Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q1 2023 · 10-Q
Revenue$550.00K$550.00Kno prior Q1 2022 on file Net Income-$4.96M-$4.96MN/M vs Q1 2022 EPS Diluted-$20.89-$20.89N/M vs Q1 2022 Operating Income-$4,986,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,089,000— Margins · derivedOperating margin-906.5%
Net margin-902.2%
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end